This IOF application concerns the further development of a new production method for 18F-labeled radiopharmaceuticals based on the mixing of the radioisotope (18F) with the drug (simple reconstitution where 18F is coupled to the drug). Proof of concept has already been demonstrated for an in-house developed radiopharmaceutical used for the diagnosis of prostate cancer, which is already successfully applied in the clinical routine of UZGent. A patent application (EP 24222828.6) has been filed for our new production method. The aim is to obtain additional data for other radiopharmaceuticals during the priority year and to scale up the process to an industrial level. In this way, we hope to attract interest from radiopharmaceutical companies with the aim of licensing the technology.